ClinicalTrials.gg
CompletedNCT02005562Updated Nov 11, 2015Results posted

OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

A Phase 3 interventional study of mycophenolate mofetil and mycophenolate mofetil in Kidney Transplantation, sponsored by Hoffmann-La Roche. Completed at 24 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study will compare the incidence of acute clinical or subclinical rejection between immunosuppression with CellCept at a starting dose of 3mg po daily with therapeutic drug monitoring and standard immunosuppression with CellCept and a fixed dose of 2g po daily, in kidney transplant recipients receiving induction by anti-IRL2, cyclosporine therapy, and early discontinuation of steroids. Patients will be randomized to one of the two treatment arms. The anticipated time on study treatment is 52 weeks.

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, aged 18-75 years of age;
  • in receipt of first donor kidney;
  • eligible to receive treatment comprising IRL2, CellCept, cyclosporine and ;
  • eligible to receive oral treatment from the first day post-transplantation.

Exclusion criteria

Exclusion Criteria:

  • patients receiving a second or subsequent kidney transplant, or multi-organ transplant;
  • history of in the last 5 years (except successfully treated squamous cell or basal cell cancer and cervical cancer in situ);
  • patients with active and/or , or infection.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    Mycophenolate Mofetil, Adapted Dose

    Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours \[q12h\]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.

    Drug: mycophenolate mofetil · Drug: anti-IL-2R · Drug: methylprednisolone · Drug: cyclosporine

  • Active comparator
    Mycophenolate Mofetil, Fixed Dose

    Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.

    Drug: mycophenolate mofetil · Drug: anti-IL-2R · Drug: methylprednisolone · Drug: cyclosporine

Interventions

  • 3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).

    Also known as: CellCept

  • 2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.

    Also known as: CellCept

  • Druganti-IL-2R

    Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.

  • 500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.

    Also known as: Solumedrol

  • 100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12

    BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10 percent (%) compared to baseline (BL) values and BPAR of Grade greater than or equal to (≥) 1 according to Banff 1997 classification at Week 12.

    Time frame: Week 12

Secondary outcomes

  1. Serum Creatinine Values [Micromoles Per Liter (µmol/L)]

    The mean serum creatinine values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52.

    Time frame: Weeks 2, 4, 6, 12, 16, 26, 39, and 52

  2. Creatinine Clearance Values Estimated With the Cockcroft-Gault Equation (Milliliters Per Minute [mL/Min])

    The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the Cockcroft-Gault equation.

    Time frame: Weeks 2, 4, 6, 12, 16, 26, 39, and 52

  3. Creatinine Clearance Values Estimated With the Modification of Diet in Renal Disease (MDRD) Simplified Equation

    The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the MDRD simplified equation. For males, the MDRD simplified equation was defined as MDRD (mL/min/1.73 square meters \[m\^2\]) =186 multiplied by (\*) serum creatinine in mg/L raised to the power of (\^) -1.154 \* age \^ -0.203. For females, the MDRD simplified equation was defined as MDRD (mL/min/1.73 m\^2) = males formula \* 0.742.

    Time frame: Weeks 2, 4, 6, 12, 16, 26, 39, and 52

  4. Time to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event

    BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52

  5. Time to Occurrence of First BPAR Between Day 0 and Week 52

    BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52

  6. Percentage of Participants With at Least One BPAR at Week 12 and Week 52

    BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Weeks 12 and 52

  7. Graft Histology - Percentage of Participants With at Least One Borderline Lesion at Week 12 and Week 52

    Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Weeks 12 and 52

  8. Graft Histology - Percentage of Participants With at Least One Chronic Graft Nephropathy at Week 12 and Week 52

    Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Weeks 12 and 52

  9. Graft Loss - Percentage of Participants With an Event

    Graft loss was defined as physical loss (nephrectomy), functional loss \[necessitating maintenance dialysis for greater than (\>)8 weeks\], retransplant or death. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52

  10. Time to Graft Loss

    The median time, in days, from randomization to graft loss event. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52

  11. Participant Survival

    Participants survival was defined as the percentage of participants living with or without a functioning graft between Weeks 0 and 52. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

    Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52

07

Results

Posted Nov 11, 2015

Participant flow

Participant flow — Overall Study
MilestoneMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Started127125
Transplanted126121
Completed115110
Not completed1215
Withdrew: Death22
Withdrew: Graft loss76
Withdrew: Withdrawal by subject22
Withdrew: No transplant14
Withdrew: Physician decision01

Outcome measures

PrimaryPercentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12

BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10 percent (%) compared to baseline (BL) values and BPAR of Grade greater than or equal to (≥) 1 according to Banff 1997 classification at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12
percentage of participantsMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 1224.219.8
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Chi-squared · p = 0.479
SecondarySerum Creatinine Values [Micromoles Per Liter (µmol/L)]

The mean serum creatinine values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52.

Time frame:
Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Mean · µmol/L
Serum Creatinine Values [Micromoles Per Liter (µmol/L)]
µmol/LMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Week 2 (n=120,114)202.41 ± 144.80201.31 ± 130.79
Week 4 (n=119,113)168.92 ± 95.66174.86 ± 77.67
Week 6 (n=119,113)155.74 ± 84.01158.96 ± 59.36
Week 12 (n=117,112)140.80 ± 53.18147.70 ± 50.38
Week 16 (n=116,112)145.48 ± 83.00148.48 ± 71.83
Week 26 (n=115,112)131.73 ± 42.20143.73 ± 46.87
Week 40 (n=114,108)136.24 ± 45.84141.89 ± 47.19
Week 52 (n=115,110)148.62 ± 124.30144.72 ± 47.37
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · ANOVA · p = 0.6736
SecondaryCreatinine Clearance Values Estimated With the Cockcroft-Gault Equation (Milliliters Per Minute [mL/Min])

The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the Cockcroft-Gault equation.

Time frame:
Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Mean · mL/min
Creatinine Clearance Values Estimated With the Cockcroft-Gault Equation (Milliliters Per Minute [mL/Min])
mL/minMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Week 2 (n=120,114)46.68 ± 21.0545.26 ± 18.93
Week 4 (n=119,113)51.03 ± 19.1746.73 ± 18.11
Week 6 (n=119,113)53.66 ± 20.9449.77 ± 19.05
Week 12 (n=117,112)56.55 ± 19.4053.01 ± 20.14
Week 16 (n=116,112)56.55 ± 20.1453.49 ± 19.72
Week 26 (n=115,112)60.21 ± 21.3555.18 ± 20.52
Week 40 (n=114,108)59.17 ± 19.8656.81 ± 21.81
Week 52 (n=115,110)58.29 ± 20.4256.45 ± 22.02
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · ANOVA · p = 0.2172
SecondaryCreatinine Clearance Values Estimated With the Modification of Diet in Renal Disease (MDRD) Simplified Equation

The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the MDRD simplified equation. For males, the MDRD simplified equation was defined as MDRD (mL/min/1.73 square meters \[m\^2\]) =186 multiplied by (\*) serum creatinine in mg/L raised to the power of (\^) -1.154 \* age \^ -0.203. For females, the MDRD simplified equation was defined as MDRD (mL/min/1.73 m\^2) = males formula \* 0.742.

Time frame:
Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Mean · mL/min/1.73 m^2
Creatinine Clearance Values Estimated With the Modification of Diet in Renal Disease (MDRD) Simplified Equation
mL/min/1.73 m^2Mycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Week 2 (n=120,114)40.61 ± 19.0039.60 ± 18.74
Week 4 (n=119,113)45.02 ± 16.5841.31 ± 16.70
Week 6 (n=119,113)48.12 ± 19.3244.69 ± 16.69
Week 12 (n=117,112)50.93 ± 16.2747.68 ± 16.24
Week 16 (n=116,112)50.93 ± 17.0548.52 ± 17.42
Week 26 (n=115,112)54.22 ± 16.7649.46 ± 18.64
Week 40 (n=114,108)52.23 ± 15.9450.01 ± 18.69
Week 52 (n=115,110)50.82 ± 16.3348.88 ± 18.24
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · ANOVA · p = 0.4770
SecondaryTime to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event

BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Number · percentage of participants
Time to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event
percentage of participantsMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Time to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event24.614.9
SecondaryTime to Occurrence of First BPAR Between Day 0 and Week 52

BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Median · days
Time to Occurrence of First BPAR Between Day 0 and Week 52
daysMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Time to Occurrence of First BPAR Between Day 0 and Week 52NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Log Rank · p = 0.0764
SecondaryPercentage of Participants With at Least One BPAR at Week 12 and Week 52

BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Weeks 12 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One BPAR at Week 12 and Week 52
percentage of participantsMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Week 1214.110.0
Week 529.110.0
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Fisher Exact · p = 0.418
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Fisher Exact · p = 0.841
SecondaryGraft Histology - Percentage of Participants With at Least One Borderline Lesion at Week 12 and Week 52

Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Weeks 12 and 52
Reported as:
Number · percentage of participants
Graft Histology - Percentage of Participants With at Least One Borderline Lesion at Week 12 and Week 52
percentage of participantsMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Week 127.912.4
Week 526.45.0
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Fisher Exact · p = 0.245
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Fisher Exact · p = 0.637
SecondaryGraft Histology - Percentage of Participants With at Least One Chronic Graft Nephropathy at Week 12 and Week 52

Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Weeks 12 and 52
Reported as:
Number · percentage of participants
Graft Histology - Percentage of Participants With at Least One Chronic Graft Nephropathy at Week 12 and Week 52
percentage of participantsMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Week 1220.617.4
Week 5232.534.7
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Fisher Exact · p = 0.512 (Mycophenolate Mofetil, Adapted Dose vs. Mycophenolate Mofetil, Fixed Dose at protocol biopsy at Week 12.)
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Fisher Exact · p = 0.718 (Mycophenolate Mofetil, Adapted Dose vs. Mycophenolate Mofetil, Fixed Dose at protocol biopsy at Week 52.)
SecondaryGraft Loss - Percentage of Participants With an Event

Graft loss was defined as physical loss (nephrectomy), functional loss \[necessitating maintenance dialysis for greater than (\>)8 weeks\], retransplant or death. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Number · percentage of participants
Graft Loss - Percentage of Participants With an Event
percentage of participantsMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Graft Loss - Percentage of Participants With an Event5.65.0
SecondaryTime to Graft Loss

The median time, in days, from randomization to graft loss event. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Median · days
Time to Graft Loss
daysMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Time to Graft LossNA ± NANA ± NA
Statistical analysis
  • Mycophenolate Mofetil, Adapted Dose vs Mycophenolate Mofetil, Fixed Dose · Log Rank · p = 0.860
SecondaryParticipant Survival

Participants survival was defined as the percentage of participants living with or without a functioning graft between Weeks 0 and 52. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.

Time frame:
Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Reported as:
Number · percentage of participants
Participant Survival
percentage of participantsMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Participant Survival98.498.3

Adverse events

Collected over All adverse events (AEs) were recorded from randomization (Day 0) through the end of study (Week 52).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mycophenolate Mofetil, Adapted Dose—106/127 (83.5%)120/127 (94.5%)
Mycophenolate Mofetil, Fixed Dose—94/125 (75.2%)115/125 (92%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
Kidney transplant rejectionRenal and urinary disorders49/12739/125
Cytomegalovirus infectionInfections and infestations18/1277/125
Blood creatinine increasedInvestigations15/12710/125
Renal failure acuteRenal and urinary disorders14/12711/125
Renal impairmentRenal and urinary disorders9/1279/125
Pyelonephritis acuteInfections and infestations9/1275/125
PyelonephritisInfections and infestations8/1277/125
Graft dysfunctionInjury, poisoning and procedural complications6/1276/125
DiarrhoeaGastrointestinal disorders3/1274/125
NeutropeniaBlood and lymphatic system disorders3/1273/125
Most frequent other events
Showing 10 of 26
Most frequent other events
EventMycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed Dose
AnaemiaBlood and lymphatic system disorders71/12762/125
LeukopeniaBlood and lymphatic system disorders42/12723/125
Urinary tract infectionInfections and infestations28/12731/125
Oedema peripheralGeneral disorders27/12727/125
HypertensionVascular disorders18/12722/125
Graft dysfunctionInjury, poisoning and procedural complications22/12710/125
DiarrheoaGastrointestinal disorders18/1276/125
DyslipidaemiaMetabolism and nutrition disorders13/12717/125
Diabetes mellitusMetabolism and nutrition disorders16/12712/125
Cytomegalovirus infectionInfections and infestations15/12714/125

Baseline characteristics

Intent-to-treat (ITT) population, all randomized renal transplant recipients who received at least 1 dose of MMF.

Age, Continuous
Age, Continuous(years)Mycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed DoseTotal
Mean48.4 ± 13.248.5 ± 13.048.5 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Mycophenolate Mofetil, Adapted DoseMycophenolate Mofetil, Fixed DoseTotal
Female404383
Male8678164
08

Study locations

24 sites
  • Bordeaux, 33076, France
  • Brest, 29609, France
  • Clermont-ferrand, 63000, France
  • Creteil, 94010, France
  • Dijon, 21079, France
  • La Tronche, 38700, France
  • Le Kremlin-bicetre, 94275, France
  • Lille, 59037, France
  • Limoges, 87042, France
  • Montpellier, 34295, France
  • Nantes, 44035, France
  • Nice, 06002, France
  • Paris, 75018, France
  • Paris, 75475, France
  • Paris, 75743, France
  • Paris, 75970, France
  • Poitiers, 86021, France
  • Rennes, 35033, France
  • Salouel, 80480, France
  • Strasbourg, 67091, France
  • Suresnes, 92151, France
  • Toulouse, 31054, France
  • Tours, 37044, France
  • Vandoeuvre-les-nancy, 54511, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2013
First posted
Dec 9, 2013
Start
May 2006
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Nov 11, 2015
Last update
Nov 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02005562
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
May 2006
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Nov 11, 2015
Last update
Nov 11, 2015

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mycophenolic Acid · Cyclosporine

Start the discussion